Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report released on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Performance

Brainstorm Cell Therapeutics stock opened at $1.66 on Friday. The stock has a market cap of $9.47 million, a PE ratio of -0.35 and a beta of 0.26. The stock has a 50-day moving average of $2.02 and a two-hundred day moving average of $2.53. Brainstorm Cell Therapeutics has a one year low of $1.05 and a one year high of $11.89.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.